HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Nick Finer Selected Research

sibutramine (Meridia)

11/2013Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial.
1/2013Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individuals.
9/2010Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
1/2010The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period.
8/2009Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial.
1/2009Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial.
11/2008Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial.
12/2007Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial.
8/2003Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Nick Finer Research Topics

Disease

10Weight Loss (Weight Reduction)
06/2014 - 08/2003
10Overweight
06/2014 - 11/2006
5Obesity
06/2014 - 08/2003
5Cardiovascular Diseases (Cardiovascular Disease)
11/2013 - 12/2007
3Myocardial Infarction
11/2013 - 09/2010
3Heart Arrest (Cardiac Arrest)
11/2013 - 09/2010
3Stroke (Strokes)
11/2013 - 09/2010
2Type 2 Diabetes Mellitus (MODY)
09/2010 - 01/2010
2Body Weight (Weight, Body)
08/2009 - 08/2003
2Nausea
11/2008 - 11/2006
1Weight Gain
12/2014
1Epilepsy (Aura)
06/2014
1Migraine Disorders (Migraine)
06/2014
1Type 1 Diabetes Mellitus (Autoimmune Diabetes)
08/2013
1Headache (Headaches)
11/2008
1Sleep Initiation and Maintenance Disorders (Insomnia)
11/2008
1Tachycardia (Tachyarrhythmias)
11/2008
1Hypertension (High Blood Pressure)
11/2008
1Constipation
11/2008
1Hypopituitarism (Sheehan's Syndrome)
02/2007
1Dizziness (Lightheadedness)
11/2006
1Mood Disorders (Mood Disorder)
11/2006
1Anorexia
05/2006

Drug/Important Bio-Agent (IBA)

9sibutramine (Meridia)FDA Link
11/2013 - 08/2003
2Insulin (Novolin)FDA Link
12/2014 - 11/2013
2Metformin (Glucophage)FDA LinkGeneric
11/2013 - 11/2006
2Uric Acid (Urate)IBA
01/2013 - 01/2009
1Anti-Obesity Agents (Antiobesity Drugs)IBA
06/2014
1Phentermine (Adipex-P)FDA LinkGeneric
06/2014
1topiramate (Topamax)FDA LinkGeneric
06/2014
1MicronutrientsIBA
02/2013
1orlistat (Xenical)FDA Link
02/2013
1antineoplaston A10 (A 10)IBA
02/2013
1CB1 Cannabinoid Receptor (CB1 Receptor)IBA
07/2011
1LipidsIBA
01/2010
1BilirubinIBA
08/2009
1Glucose (Dextrose)FDA LinkGeneric
01/2009
1HDL CholesterolIBA
02/2007
1rimonabantIBA
11/2006
1Fatty Acid Synthetase Complex (Fatty Acid Synthase)IBA
05/2006
1TamoxifenFDA LinkGeneric
05/2006
1Malonyl Coenzyme A (Malonyl CoA)IBA
05/2006

Therapy/Procedure

3Drug Therapy (Chemotherapy)
06/2014 - 01/2006
3Bariatric Surgery
08/2013 - 09/2007
2Resuscitation
11/2013 - 09/2010
1Fat-Restricted Diet (Diet, Fat Restricted)
02/2013